Nuvation Bio (NUVB) | Stock Overview & Key Data
Nuvation Bio Performance Comparison
Stock Range
Today's Range
Low: $3.08
High: $3.35
on September 12, 2025
52 Week Range
Low: $1.54
High: $4.09
on April 7, 2025
on September 5, 2025
All-Time High: $15.23 on May 24, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.1B
EPS
-0.38
P/E Ratio (TTM)
-1.49
Forward P/E
-4.98
P/B Ratio
2.88
PEG Ratio
0.02
Div. Yield
N/A
ROE
-44.84%
Beta
1.367
Debt to Equity
15.49
Financial Highlights
Profitability
Gross Margin
46.70%
Operating Margin
-1,315.72%
Profit Margin
10.10%
Returns and Earnings
Return on Assets (TTM)
20.17%
Return on Equity (TTM)
-44.84%
EBITDA
$201.5M
Net Income (TTM)
$-202.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.04
Quarterly Revenue Growth (YoY)
236.80%
Quarterly Earnings Growth (YoY)
236.79%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Nuvation Bio NUVB | 1.07B Small-cap | -19.49% | 35.34% | 73.48% | 40.18% | 21.24% | 2.95% | 38.33% | -71.45% |
| Vertex VRTX | 101.15B Large-cap | -0.40% | 1.74% | -14.24% | -20.36% | -2.77% | -18.72% | 36.18% | 48.66% |
| Alnylam ALNY | 61.07B Large-cap | 3.07% | 8.36% | 52.92% | 92.18% | 99.42% | 75.61% | 118.70% | 252.21% |
| Adaptive ADPT | 1.92B Small-cap | -1.87% | -0.39% | 21.13% | 65.49% | 103.72% | 173.54% | 65.27% | -72.79% |
| Dyne Therapeutics DYN | 1.87B Small-cap | -7.52% | 13.17% | -9.06% | 6.39% | -48.35% | -61.39% | -3.66% | -42.32% |
| Harmony Biosciences HRMY | 1.86B Small-cap | -10.00% | -8.68% | -2.82% | -3.60% | -7.01% | -16.76% | -26.12% | -3.60% |
Ownership & Short Interest
Insider Ownership
19.03%
Institutional Ownership
66.74%
Shares Short
68M
Short Ratio
15.08
Short % of Shares Outstanding
32.47%
Average 10-Day Volume
8M
Average 90-Day Volume
6M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NUVB's 52-week high and low?
- In the last 52 weeks, Nuvation Bio reached a high of $4.09 (on September 5, 2025) and a low of $1.54 (on April 7, 2025).
- What is the market cap and P/E ratio for NUVB?
- Curious about Nuvation Bio's size and valuation? Its market capitalization stands at 1.07B. When it comes to valuation, the P/E ratio (trailing twelve months) is -1.49, and the forward P/E (looking ahead) is -4.98.
- Does NUVB pay dividends? If so, what's the yield?
- As for dividends, Nuvation Bio isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nuvation Bio's main competitors or similar companies to consider before investing?
When looking at Nuvation Bio, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.15B Healthcare Biotechnology -18.72% 36.18% Alnylam
ALNY61.07B Healthcare Biotechnology 75.61% 118.70% Adaptive
ADPT1.92B Healthcare Biotechnology 173.54% 65.27% Dyne Therapeutics
DYN1.87B Healthcare Biotechnology -61.39% -3.66% Harmony Biosciences
HRMY1.86B Healthcare Biotechnology -16.76% -26.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nuvation Bio Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Nuvation Bio's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -44.84%, the Debt to Equity ratio from the most recent quarter is 15.49, and its Gross Profit Margin stands at 46.70%.
- What is the recent revenue and earnings growth for NUVB?
- Looking at Nuvation Bio's growth, its revenue over the trailing twelve months (TTM) was $14M. Compared to the same quarter last year (YoY), quarterly revenue grew by 236.80%, and quarterly earnings saw a YoY growth of 236.79%.
- How much of NUVB stock is held by insiders and institutions?
- Wondering who owns Nuvation Bio stock? Company insiders (like executives and directors) hold about 19.03% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 66.74%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.